Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
Fiche publication
Date publication
avril 2019
Journal
JAMA oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BIBEAU Frédéric
Tous les auteurs :
Cohen R, Hain E, Buhard O, Guilloux A, Bardier A, Kaci R, Bertheau P, Renaud F, Bibeau F, Fléjou JF, André T, Svrcek M, Duval A
Lien Pubmed
Résumé
Primary resistance to immune checkpoint inhibitors is observed in 10% to 40% of patients with metastatic colorectal cancer (mCRC) displaying microsatellite instability (MSI) or defective mismatch repair (dMMR).
Mots clés
Adult, Antineoplastic Agents, Immunological, therapeutic use, Colorectal Neoplasms, diagnosis, DNA Mismatch Repair, Diagnostic Errors, Drug Resistance, Neoplasm, Female, Humans, Male, Microsatellite Instability, Middle Aged, Predictive Value of Tests, Prospective Studies, Retrospective Studies
Référence
JAMA Oncol. 2019 Apr 1;5(4):551-555